Abstract | BACKGROUND: Effective intra-oesophageal acid suppression can be achieved with lansoprazole. The daily dosage could be influenced by the presence of hiatal hernia. AIM: METHODS: Fifty patients with complications or atypical manifestations of gastro-oesophageal reflux disease were given lansoprazole, 30 mg once daily. Three to four weeks after the start of treatment, patients underwent oesophageal pH monitoring while on therapy. If the results were still abnormal, the lansoprazole dosage was doubled and 24-h pH-metry was repeated 20-30 days thereafter. RESULTS: A 30-mg daily dosage of lansoprazole normalized oesophageal acid exposure in 70% of cases, whilst a 60-mg daily dosage was necessary in the remainder: the two groups differed only in the presence of hiatal hernia (28% vs. 100%, respectively; P=0.000). Effective intra-oesophageal acid suppression was obtained in all 25 patients without hiatal hernia with the 30-mg daily dosage of lansoprazole. CONCLUSIONS:
|
Authors | M Frazzoni, E De Micheli, A Grisendi, V Savarino |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 16
Issue 5
Pg. 881-6
(May 2002)
ISSN: 0269-2813 [Print] England |
PMID | 11966495
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Lansoprazole
- Omeprazole
|
Topics |
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Anti-Ulcer Agents
(administration & dosage, therapeutic use)
- Dose-Response Relationship, Drug
- Gastroesophageal Reflux
(classification, complications, drug therapy)
- Hernia, Hiatal
(complications)
- Humans
- Hydrogen-Ion Concentration
- Lansoprazole
- Manometry
- Middle Aged
- Omeprazole
(administration & dosage, analogs & derivatives, therapeutic use)
- Proton Pump Inhibitors
|